{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:19:02Z","timestamp":1791256742257,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"45","license":[{"start":{"date-parts":[[2015,2,23]],"date-time":"2015-02-23T00:00:00Z","timestamp":1424649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,2,23]],"date-time":"2015-02-23T00:00:00Z","timestamp":1424649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2015,11,5]]},"DOI":"10.1038\/onc.2015.16","type":"journal-article","created":{"date-parts":[[2015,2,23]],"date-time":"2015-02-23T05:57:30Z","timestamp":1424671050000},"page":"5607-5616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells"],"prefix":"10.1038","volume":"34","author":[{"given":"N","family":"Komatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,23]]},"reference":[{"key":"BFonc201516_CR1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/0968-0004(93)90019-J","volume":"18","author":"E Nishida","year":"1993","unstructured":"Nishida E, Gotoh Y . The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 1993; 18: 128\u2013131.","journal-title":"Trends Biochem Sci"},{"key":"BFonc201516_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761\u2013774.","journal-title":"Nat Rev Cancer"},{"key":"BFonc201516_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein IB . Cancer. Addiction to oncogenes\u2014the Achilles heal of cancer. Science 2002; 297: 63\u201364.","journal-title":"Science"},{"key":"BFonc201516_CR4","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1101\/gad.1609907","volume":"21","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Settleman J . Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21: 3214\u20133231.","journal-title":"Genes Dev"},{"key":"BFonc201516_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J, Haber DA . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169\u2013181.","journal-title":"Nat Rev Cancer"},{"key":"BFonc201516_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pharmthera.2013.10.001","volume":"141","author":"C Neuzillet","year":"2014","unstructured":"Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E . MEK in cancer and cancer therapy. Pharmacol Ther 2014; 141: 160\u2013171.","journal-title":"Pharmacol Ther"},{"key":"BFonc201516_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature04304","volume":"439","author":"DB Solit","year":"2006","unstructured":"Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358\u2013362.","journal-title":"Nature"},{"key":"BFonc201516_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","volume":"15","author":"A Singh","year":"2009","unstructured":"Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N et al. A gene expression signature associated with \u2018K-Ras addiction\u2019 reveals regulators of EMT and tumor cell survival. Cancer Cell 2009; 15: 489\u2013500.","journal-title":"Cancer Cell"},{"key":"BFonc201516_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.bcp.2013.02.017","volume":"85","author":"M Rebucci","year":"2013","unstructured":"Rebucci M, Michiels C . Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 2013; 85: 1219\u20131226.","journal-title":"Biochem Pharmacol"},{"key":"BFonc201516_CR10","doi-asserted-by":"publisher","first-page":"18351","DOI":"10.1073\/pnas.0907325106","volume":"106","author":"ML Sos","year":"2009","unstructured":"Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 2009; 106: 18351\u201318356.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201516_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/msb.2013.29","volume":"9","author":"B Klinger","year":"2013","unstructured":"Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D et al. Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol 2013; 9: 673.","journal-title":"Mol Syst Biol"},{"key":"BFonc201516_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100\u2013103.","journal-title":"Nature"},{"key":"BFonc201516_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12441","volume":"501","author":"G Hatzivassiliou","year":"2013","unstructured":"Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 2013; 501: 232\u2013236.","journal-title":"Nature"},{"key":"BFonc201516_CR14","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1073\/pnas.0900780106","volume":"106","author":"CA Pratilas","year":"2009","unstructured":"Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009; 106: 4519\u20134524.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201516_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1158\/0008-5472.CAN-08-3389","volume":"69","author":"OK Mirzoeva","year":"2009","unstructured":"Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R et al. Basal subtype and MAPK\/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009; 69: 565\u2013572.","journal-title":"Cancer Res"},{"key":"BFonc201516_CR16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351\u20131356.","journal-title":"Nat Med"},{"key":"BFonc201516_CR17","doi-asserted-by":"crossref","unstructured":"Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM et al. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal 2013. 6\u2013ra20.","DOI":"10.1126\/scisignal.2003483"},{"key":"BFonc201516_CR18","doi-asserted-by":"crossref","unstructured":"LoRusso P, Shapiro G, Pandya SS, Kwak EL, Jones C, Belvin M et al. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. J Clin Oncol 2012. 30.","DOI":"10.1200\/jco.2012.30.15_suppl.2566"},{"key":"BFonc201516_CR19","doi-asserted-by":"crossref","unstructured":"Speranza G, Kinders RJ, Khin S, MK Weil, Do KT, Horneffer Y et al. Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC). J Clin Oncol 2012. 30.","DOI":"10.1200\/jco.2012.30.15_suppl.3529"},{"key":"BFonc201516_CR20","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1091\/mbc.e11-01-0072","volume":"22","author":"N Komatsu","year":"2011","unstructured":"Komatsu N, Aoki K, Yamada M, Yukinaga H, Fujita Y, Kamioka Y et al. Development of an optimized backbone of FRET biosensors for kinases and GTPases. Mol Biol Cell 2011; 22: 4647\u20134656.","journal-title":"Mol Biol Cell"},{"key":"BFonc201516_CR21","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.1158\/0008-5472.CAN-08-1430","volume":"68","author":"BB Friday","year":"2008","unstructured":"Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008; 68: 6145\u20136153.","journal-title":"Cancer Res"},{"key":"BFonc201516_CR22","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-09-1883","volume":"16","author":"PM LoRusso","year":"2010","unstructured":"LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK\/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010; 16: 1924\u20131937.","journal-title":"Clin Cancer Res"},{"key":"BFonc201516_CR23","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1074\/jbc.M900301200","volume":"284","author":"CC Thoreen","year":"2009","unstructured":"Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023\u20138032.","journal-title":"J Biol Chem"},{"key":"BFonc201516_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ccr.2010.05.023","volume":"18","author":"QB She","year":"2010","unstructured":"She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010; 18: 39\u201351.","journal-title":"Cancer Cell"},{"key":"BFonc201516_CR25","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1002\/j.1460-2075.1996.tb00602.x","volume":"15","author":"P Rodriguez-Viciana","year":"1996","unstructured":"Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J . Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 1996; 15: 2442\u20132451.","journal-title":"EMBO J"},{"key":"BFonc201516_CR26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J . The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011; 36: 320\u2013328.","journal-title":"Trends Biochem Sci"},{"key":"BFonc201516_CR27","doi-asserted-by":"publisher","first-page":"13489","DOI":"10.1073\/pnas.0405659101","volume":"101","author":"PP Roux","year":"2004","unstructured":"Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J . Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 2004; 101: 13489\u201313494.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201516_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1074\/jbc.M110.159046","volume":"286","author":"A Carriere","year":"2011","unstructured":"Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, Thibault P et al. ERK1\/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 2011; 286: 567\u2013577.","journal-title":"J Biol Chem"},{"issue":"196","key":"BFonc201516_CR29","doi-asserted-by":"publisher","first-page":"196ra98","DOI":"10.1126\/scitranslmed.3005753","volume":"5","author":"Ryan B. Corcoran","year":"2013","unstructured":"Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 2013; 5 196ra198.","journal-title":"Science Translational Medicine"},{"key":"BFonc201516_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nmeth.1323","volume":"6","author":"K Yusa","year":"2009","unstructured":"Yusa K, Rad R, Takeda J, Bradley A . Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 2009; 6: 363\u2013369.","journal-title":"Nat Methods"},{"key":"BFonc201516_CR31","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1534\/genetics.166.2.895","volume":"166","author":"K Kawakami","year":"2004","unstructured":"Kawakami K, Noda T . Transposition of the Tol2 element, an Ac-like element from the Japanese medaka fish Oryzias latipes, in mouse embryonic stem cells. Genetics 2004; 166: 895\u2013899.","journal-title":"Genetics"},{"key":"BFonc201516_CR32","doi-asserted-by":"crossref","first-page":"8150","DOI":"10.1128\/JVI.72.10.8150-8157.1998","volume":"72","author":"H Miyoshi","year":"1998","unstructured":"Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM . Development of a self-inactivating lentivirus vector. J Virol 1998; 72: 8150\u20138157.","journal-title":"J Virol"},{"key":"BFonc201516_CR33","doi-asserted-by":"publisher","first-page":"13567","DOI":"10.1073\/pnas.1834876100","volume":"100","author":"T Akagi","year":"2003","unstructured":"Akagi T, Sasai K, Hanafusa H . Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc Natl Acad Sci USA 2003; 100: 13567\u201313572.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201516_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"DH Kim","year":"2002","unstructured":"Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163\u2013175.","journal-title":"Cell"},{"key":"BFonc201516_CR35","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/nprot.2009.175","volume":"4","author":"K Aoki","year":"2009","unstructured":"Aoki K, Matsuda M . Visualization of small GTPase activity with fluorescence resonance energy transfer-based biosensors. Nat Protoc 2009; 4: 1623\u20131631.","journal-title":"Nat Protoc"},{"key":"BFonc201516_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","volume":"9","author":"N Otsu","year":"1979","unstructured":"Otsu N . A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern 1979; 9: 62\u201366.","journal-title":"IEEE Trans Syst Man Cybern"},{"key":"BFonc201516_CR37","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1111\/febs.12852","volume":"281","author":"Y Fujita","year":"2014","unstructured":"Fujita Y, Komatsu N, Matsuda M, Aoki K . Fluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs. FEBS J 2014; 281: 3177\u20133192.","journal-title":"FEBS J"},{"key":"BFonc201516_CR38","doi-asserted-by":"crossref","unstructured":"Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA . BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010. 3\u2013ra84.","DOI":"10.1126\/scisignal.2001148"},{"key":"BFonc201516_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.molcel.2013.09.015","volume":"52","author":"K Aoki","year":"2013","unstructured":"Aoki K, Kumagai Y, Sakurai A, Komatsu N, Fujita Y, Shionyu C et al. Stochastic ERK activation induced by noise and cell-to-cell propagation regulates cell density-dependent proliferation. Mol Cell 2013; 52: 529\u2013540.","journal-title":"Mol Cell"},{"key":"BFonc201516_CR40","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nmeth.1226","volume":"5","author":"A Mortazavi","year":"2008","unstructured":"Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B . Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5: 621\u2013628.","journal-title":"Nat Methods"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc201516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201516","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:30:06Z","timestamp":1647880206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc201516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,23]]},"references-count":40,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2015,11,5]]}},"alternative-id":["BFonc201516"],"URL":"https:\/\/doi.org\/10.1038\/onc.2015.16","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725364702.793517745","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,23]]},"assertion":[{"value":"2 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}